Related Experiment Video
Updated: Jun 18, 2025
05:42
Author Spotlight: Unlocking the Mysteries of Oral Potential Malignancies
Published on: August 11, 2023
1.1K
Synchronous cemento-ossifying fibromas: a systematic review.
B-L Neumann1, E-M Mendes, B-B Só
1Universidade Federal do Rio Grande do Sul Faculdade de Odontologia, Rua Ramiro Barcelos, 2492, sala 503 CEP: 90035-003, Santana, Porto Alegre RS, Brazil manomartins@gmail.com.
Medicina Oral, Patologia Oral Y Cirugia Bucal
|August 1, 2024
Summary
Synchronous cemento-ossifying fibromas (COF) are rare, predominantly affecting females in their 30s. The most frequent presentation involves simultaneous occurrence in both the mandible and maxilla.
Area of Science:
- Oral and Maxillofacial Pathology
- Dental Oncology
- Head and Neck Surgery
Background:
- This systematic review synthesizes data on synchronous cemento-ossifying fibromas (COF), rare tumors presenting simultaneously.
- It analyzes the demographic and clinicopathological features of these synchronous COF cases.
Approach:
- A comprehensive literature search was conducted across major databases (PubMed, Web of Science, Scopus, EMBASE, LILACS) adhering to PRISMA guidelines.
- Case reports and series of synchronous COF were included, supplemented by manual searches and grey literature assessment.
- Descriptive statistical analysis was employed to summarize findings.
Key Points:
- Twenty synchronous COF cases from 19 studies were analyzed, with a mean age at diagnosis of 35 years.
- A female predilection (60%) was observed, and 65% of cases involved simultaneous mandibular and maxillary lesions.
- First-degree relatives had COF in 10% of cases, and differential diagnoses included florid cemento-osseous dysplasia and ameloblastic fibroodontoma.
Conclusions:
- Synchronous cemento-ossifying fibromas (COF) are uncommon, with a higher incidence in females during their third decade of life.
- The most characteristic clinical presentation is bilateral involvement of the mandible and maxilla.
- Surgical enucleation/excision was the primary treatment, with recurrence noted in 30% of follow-up cases.
